About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

NCT04497649·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Sherief Abd-Elsalam, ass. prof.
CONTACT
00201147773440 sheriefabdelsalam@yahoo.com
sherief abd-elsalan, ass. prof.
CONTACT
00201147773440 sheriefabdelsalam@yahoo.com

Lead

Tanta University

The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

COVID 19 positive patients

You may not be if

COVID-19 patients with critical manifestations.
Sepsis.
Acute respiratory distress syndrome (ARDS).
Decompensated liver disease (Child-Pugh class B or C disease).
Chronic renal impairment.
Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….).
Ischemic heart disease within the last 6 months.
Chronic pulmonary disease.
Malignancy.
Pregnancy or breastfeeding.
Hypersensitivity to sofosbuvir or ribavirin.
Patients with organ transplant.
Unwilling to participate in our study

The record

StatusUnknown

PhasePhase 2–3

Taking part100

StartedJul 2020

UpdatedDec 3, 2020

Conditions

Where1

Cairo and Tanta Universitities
Tanta, Egypt

Clareo Health | Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients